ESR1 and breast carcinoma: Cyclin-dependent kinase 4/6 (CDK4/6) has now become a promising strategy for HER2-positive, HR-positive breast cancer treatment as it is the downstream of the estrogen receptor (ER) and HER2 pathways, as well as many other cellular pathways inducing resistance to HER2-targeted therapies (12).